Overview

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer

Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute, Naples